Author(s):
Bhoomi Choudhary, Anuradha P. Prajapati, Kantilal B. Narkhede, Sachin B Narkhede, Shailesh Luhar, Richa Singh
Email(s):
anuradha@ssgsalvav.in
DOI:
10.52711/2231-3915.2025.00011 
Address:
Bhoomi Choudhary*, Anuradha P. Prajapati, Kantilal B. Narkhede, Sachin B Narkhede, Shailesh Luhar, Richa Singh
Department of Pharmaceutics, Smt. B.N.B. Swaminarayan Pharmacy College, Salvav-Vapi, Gujarat Technology University, Gujarat - 396191, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to motor symptoms such as tremor, rigidity, bradykinesia, and postural instability. Non-motor symptoms including cognitive decline, depression, and autonomic dysfunction also significantly affect patients’ quality of life. While pharmacological therapies like levodopa provide initial relief, their long-term use often results in complications such as motor fluctuations and dyskinesias. Electroceuticals have emerged as an innovative treatment approach that targets the brain’s electrical activity to restore functional neural circuits. This review highlights key electroceutical strategies in PD management, focusing primarily on deep brain stimulation (DBS), which involves implanting electrodes into regions like the subthalamic nucleus or globus pallidus interna to deliver electrical impulses. DBS has shown efficacy in improving motor symptoms and reducing medication needs in advanced PD. Other neuromodulation techniques such as vagus nerve stimulation (VNS) and transcranial electrical stimulation (TES) are also being explored for their potential to improve both motor and non-motor symptoms through neuroplastic changes and neurotransmitter modulation. Despite challenges such as surgical risks and cost, electroceuticals represent a promising advancement in PD treatment, offering personalized, circuit-based interventions beyond traditional pharmacotherapy.
Cite this article:
Bhoomi Choudhary, Anuradha P. Prajapati, Kantilal B. Narkhede, Sachin B Narkhede, Shailesh Luhar, Richa Singh. Central Nervous System implants in Parkinson’s disease: Emerging trends and future perspectives. International Journal of Technology. 2025; 15(2):56-1. doi: 10.52711/2231-3915.2025.00011
Cite(Electronic):
Bhoomi Choudhary, Anuradha P. Prajapati, Kantilal B. Narkhede, Sachin B Narkhede, Shailesh Luhar, Richa Singh. Central Nervous System implants in Parkinson’s disease: Emerging trends and future perspectives. International Journal of Technology. 2025; 15(2):56-1. doi: 10.52711/2231-3915.2025.00011 Available on: https://ijtonline.com/AbstractView.aspx?PID=2025-15-2-2
REFERENCES:
1. Sivasubramanian N. Evidence based nursing education and practice. Asian J Nurs Educ Res. 2011 Jan-Mar;1(1):19-22.
2. Roja Princy. Multi methodology – research methodology for psychiatric nursing. Asian J Nurs Educ Res. 2011 Oct-Dec;1(4):120-2.
3. Patil PA, Patil DR, Jain AS, Shaikh AZ, Shaikh SR, Pawar SP. A review on Parkinson disease. Res J Sci Technol. 2025;17(3):231-8.
4. Bhong P, Ingale S, Jadhav P. Molecular mechanisms involved in pathogenesis of Parkinson's disease. Res J Pharm Technol. 2024;17(10):5167-74.
5. Acharya S, Meenambiga SS. Nanotechnology in Parkinson's disease – a review. Res J Pharm Technol. 2020;13(4):1965-9.
6. Patel YA, Narkhede K, Prajapati A, Narkhede S, Luhar S. AI-Driven Pharmacogenomics: The Future of Personalized Medicine . Asian J Pharm Technol. 2025;15(1):51-6.
7. Rani M, Sharma V. Medical implants: an overview, innovation and future prospects. Asian J Pharm Technol. 2025;15(2):157-65.
8. Kim WY. Design and implementation of electroceutical for neurotherapy. Int J Technol. 2021;11(2):63-9.
9. Prasad J, Netam AK, Singh R, Sahu M, Satapathy T, Rao SP, Baghel P, Sahu MK. Therapeutic approaches for the management of Parkinson’s disease. Res J Pharmacology Pharmacodyn. 2019;11(1):46-52.
10. Anoop Narayanan V, Narayana Charyulu R. Pharmacoelectronics and electropharmaceutics: the arts and science of electronic drug delivery. Res J Pharm Technol. 2017;10(10):3544-8.
11. M. M. Kachhi, S. R. Shinde and C. D. Bobade * School of Health Science and Technology, Department of Pharmaceutical Sciences, Dr. Vishwananth Karad MIT World Peace University, Kothrud, Pune - 411038, Maharashtra, India.
12. Lee SK, Jeakins GS, Tukiainen A, Hewage E and Armitage OE: Next-Generation Bioelectric Medicine: Harnessing the Therapeutic Potential of Neural Implants. Bioelectricity 2020; 2(4): 321-327. doi: 10.1089/bioe.2020.0044. Epub 2020 Dec 16. PMID: 34476364; PMCID: PMC8370382.
13. Lo MC, Widge AS. Closed-loop neuromodulation systems: Next-generation treatments for psychiatric illness. Int Rev Psychiatry. 2017;29(2)
14. Birmingham K, Gradinaru V, Anikeeva P, Grill WM, Pikov V, McLaughlin B, et al. Bioelectronic medicines: A research roadmap. Nat Rev Drug Discov. 2014;13(6):399–400.
15. Famm K, Litt B, Tracey KJ, Boyden ES, Slaoui M. A jump-start for electroceuticals. Nature. 2013;496(7444):159–161.
16. Benabid AL, Pollak P, Louveau A, Henry S, de Rougemont J. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol. 1987;50(1-6):344–346.